Key facts
| Company | ct-riecig.com |
|---|---|
| FDA office | Center for Tobacco Products |
| Letter date | May 8, 2026 |
| Subject / product | Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded |
| CFR citations | FDA Warning Letter |
| Response due | 15 working days from receipt (standard FDA warning-letter requirement) |
| Reference / source ID | ct-riecigcom-729612-05082026 |
What happens next
ct-riecig.com is expected to respond to FDA in writing, typically within 15 working days of the letter date, describing the specific corrective and preventive actions taken or planned for each violation cited. FDA reviews that response and any follow-up evidence, and can conduct a re-inspection to confirm the corrections were actually made. If FDA judges the response inadequate, or the underlying conditions serious enough, further action can follow, including product seizure, injunction, import alert, or civil penalties; many Warning Letters are resolved through corrective action alone. This page reflects the Warning Letter as issued and will not reflect any subsequent correction unless FDA publishes a follow-up record. FDA issues Warning Letters after an inspection or other review when it believes a firm has significantly violated FDA regulations; the letter itself is a notice, not a final adjudication.
Violations explained
FDA Warning Letter — Violations FDA cited at ct-riecig.com
WARNING LETTER ct-riecig.com MARCS-CMS 729612 — May 08, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Reference #: RW2602410 Product: Tobacco Recipient: ct-riecig.com 188 Westminster Road Unit 3 Canterbury , CT 06331 United States SDiamio1971@gmail.com info@riecig.com Issuing Office: Center for Tobacco Products United States May 8, 2026 WARNING LETTER To Whom It May Concern: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https://ct-riecig.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to consumers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. 1 Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901 of the FD&C Act (21 U.S.C. § 387a) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act. Under section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)), it is unlawful for any retailer 2 to sell a tobacco product to any person younger than 21 years of age. 3 This includes tobacco products containing nicotine from any source including cigarettes, smokeless tobacco, cigars, e-cigarettes, and nicotine pouches. Tobacco Product Sold by a Retailer to an Individual Under the Age of 21 is Misbranded Under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed by any retailer to a person younger than 21 years of age in violation of section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)). FDA has determined that your VIHO TRX 50K Puffs – Mango Tango ENDS product is misbranded under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age. Specifically, during FDA’s investigation of https://ct-riecig.com, a person younger than 21 years of age purchased a VIHO TRX 50K Puffs – Mango Tango ENDS product from your website. Conclusion and Requested Actions It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and/or injunction. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission. Please be aware that the FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007. See Section 910(a) of the FD&C Act. For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https://www.fda.gov/searchtobacco. You should take prompt action to address the violations that are referenced above, as well as any violations of the FD&C Act and FDA’s implementing regulations that are the same as or similar to the ones stated above, and take any necessary actions to bring all your
ct-riecig.com’s FDA history
Argus HQ has recorded 1 total FDA action tied to ct-riecig.com: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.
Full letter text
Read the rest of the full text
Frequently asked questions
- Is the FDA warning letter to ct-riecig.com publicly available?
- Yes. The full verbatim letter is published at fda.gov: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ct-riecigcom-729612-05082026.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- What is an FDA Warning Letter?
- An FDA Warning Letter notifies a company that FDA believes it has significantly violated FDA regulations and that prompt corrective action is required. It is issued after an inspection, sample analysis, or other FDA review, and is a notice -- not a final legal determination and not itself a penalty.
- Does this Warning Letter mean ct-riecig.com violated the law?
- FDA's letter documents violations it believes it found at ct-riecig.com. A Warning Letter is not a final adjudication of guilt; the company has an opportunity to respond and correct the cited issues, and many Warning Letters are resolved without further enforcement once FDA confirms adequate correction.
Get the next warning letter in this therapeutic area before your team hears about it secondhand.
Weekly briefing, free. Upgrade any time for daily or real-time delivery.
Related enforcement actions
Full FDA history for ct-riecig.com- Warning letter (recent): Med Shop Inc / www.medshopinc.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): ketaminetroches.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketdaxandrugs / www.ketdaxandrugs.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Legit Ketamine Suppliers / www.legitketaminesuppliers.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Store / www.ketaminestore.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Buy Keta Online / www.buyketaonline.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Troche Store / www.ketaminetrochestore.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): All Ketamine HCL / www.allketaminehcl.com — Unapproved New Drugs/Misbranded (2026-06-23) →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). ct-riecig.com — FDA Warning Letter, May 8, 2026: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/warning-letter/ct-riecig-com-729612-2026-05-08
"ct-riecig.com — FDA Warning Letter, May 8, 2026: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/warning-letter/ct-riecig-com-729612-2026-05-08.
Argus HQ Research. "ct-riecig.com — FDA Warning Letter, May 8, 2026: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/warning-letter/ct-riecig-com-729612-2026-05-08.
@misc{argushq_argushq_ai_warning_letter_ct_riecig_com_729612_2026_05_08_2026,
title = {ct-riecig.com — FDA Warning Letter, May 8, 2026: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/warning-letter/ct-riecig-com-729612-2026-05-08},
note = {Accessed: July 13, 2026}
}Source: FDA.gov — Warning Letters ↗

